Portfolio Company · Operating Co.

Elevation Pharmaceuticals

Not on record

backed byCanaan Partners

Current

a portfolio company of

Canaan Partners

Status on record: Current

PE Firm Index

Who owns Elevation Pharmaceuticals?

Elevation Pharmaceuticals is listed as a current portfolio company of Canaan Partners on Canaan Partners' own portfolio page.

Company Snapshot

Elevation Pharmaceuticals' owner on record, Canaan Partners, is a firm. Canaan Partners lists 349 companies in the index.

SectorNot on record

Parent PE firmCanaan Partners

Ownership statusCurrent

WebsiteNot on record

About the owner

Canaan Partners

Companies in the index: 349

Venture capital firm investing across technology and healthcare.

Read the Canaan Partners profile

Questions about Elevation Pharmaceuticals

Who owns Elevation Pharmaceuticals?

Elevation Pharmaceuticals is listed as a current portfolio company of Canaan Partners on Canaan Partners' own portfolio page.

Sources

Canaan Partners' page on Elevation Pharmaceuticals
Canaan Partners
https://canaan.com/companies

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Elevation Pharmaceuticals and does not provide investment advice.

Other portfolio companies of Canaan Partners

6 of 348 shown

Abyrx

Aceiss

Acesion Pharma ApS

Actio Biosciences, Inc.

ACTIVE Network

ActualyzeAI, Inc.

See the full Canaan Partners portfolio.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Canaan Partners

Status: Current

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.